Publicaties dr. P.M.P. Poortmans

2010

• Quality indicators in breast cancer care.
(M.R. Del Turco, A. Ponti, U. Bick, L. Biganzoli, G. Cserni, et al) Eur J Cancer 2010; 46: 2344-2356.
pubmed
• No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
(J. Evers, N. Kupper, D. Kessing, R. Davits, A. Engelen, et al.) Urology 2010. [geaccepteerd voor publicatie]
pubmed
• Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study.
(S. Iğdem, D.Y. Spiegel, J. Efstathiou, R.C. Miller, P.M. Poortmans, et al) Onkologie 2010. [geaccepteerd voor publicatie]
pubmed
• Factors contributing to improved local control after mastectomy in patients with breast cancer aged 40 years or younger.
(E.J.R. Lammers, P. Huibers, M.J.C. van der Sangen, L.V. van de Poll-Franse, P.M.P. Poortmans, et al) The Breast 2010; 19: 44-49.
pubmed
• Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). (O. Matzinger, I. Heimsoth, P. Poortmans, L. Collette, H. Struikmans, et al) Acta Oncol 2010; 49: 24-34.
pubmed
• Multiinstitutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines.
(A.M. van Mourik, P.H. Elkhuizen, D. Minkema, J.C. Duppen; Dutch Young Boost Study Group, C. van Vliet-Vroegindeweij) Radiother Oncol 2010; 94 :286-291.
pubmed
• Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: A retrospective rare cancer network study.
(T.D. Nguyen, D. Azria, D. Brochon, P. Poortmans, RC Miller, et al) Crit Rev Oncol Hematol 2010; 74: 66-71.
pubmed
• Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study.
(C. Onal, Y.X. Li, R.C. Miller, P. Poortmans, N. Constantinou, et al) Ann Oncol 2010. [geaccepteerd voor publicatie]
pubmed
• Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤ 40 years.
(M.J. van der Sangen, F.M. van de Wiel, P.M. Poortmans, V.C. Tjan-Heijnen, G.A. Nieuwenhuijzen, et al) Breast Cancer Res Treat 2010. [geaccepteerd voor publicatie]
pubmed
• Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.
(M. Schuurmans, J.E. Bromberg, J. Doorduijn, P. Poortmans, M.J. Taphoorn, et al) Br J Haematol 2010. [geaccepteerd voor publicatie]
pubmed
• An Interobserver Study of Prostatic Fossa Clinical Target Volume Delineation in Clinical Practice: Are Regions of Recurrence Adequately Targeted?
(Z. Symon, L. Tsvang, M. Wygoda, R. Ben-Yoseph, B.W. Corn, et al) Am J Clin Oncol 2010. [geaccepteerd voor publicatie]
pubmed




2009

• The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment.
(S. Al Uwini, N. Antonini, P.M. Poortmans, et al) Radiother Oncol 2009; 93: 87-93.
pubmed
• Duration of androgen suppression in the treatment of prostate cancer.
(M. Bolla, T.M. de Reijke, G. Van Tienhoven, A.C. van den Bergh, J. Oddens, P.M. Poortmans, et al, on behalf of the EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group) N Engl J Med 2009; 360: 2516 - 2527.
pubmed
• Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
(N. Heutte, H.H. Flechtner, N. Mounier, et al, on behalf of the EORTC-GELA H8 Trial Group) Lancet Oncol 2009; 10: 1160-1170.
pubmed
• Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
(H.A. Jones, N. Antonini, A.A. Hart, J.L. Peterse, J.-C. Horiot, et al.) J Clin Oncol 2009; 27(30): 4939-4347.
pubmed
• Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.
(O. Matzinger, F. Duclos, A. van den Bergh, C. Carrie, S. Villà, P. Kitsios, P. Poortmans, et al, on behalf of the EORTC Radiation Oncology Group) Eur J Cancer 2009; 45: 2825-2834.
pubmed
• EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.
(O. Matzinger, E. Gerber, Z. Bernstein, P. Maingon, K. Haustermans, J.F. Bosset, A. Gulyban, P. Poortmans, L. Collette, A. Kuten) Radiother Oncol 2009; 92: 164-175.
pubmed
• Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
(O. Matzinger, P. Poortmans, J.Y. Giraud, et al, on behalf of the EORTC Radiation Oncology Group) Radiother Oncol 2009; 90: 285-290.
pubmed
• Prostate cancer: what role for curative radiotherapy in elderly?
(T.D. Nguyen, D. Azria, D. Brochon, P. Poortmans, R.C. Miller) Cancer Radiother 2009; 13: 623-627.
pubmed
• Impact of the boost dose of 10Gy versus 26Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
(P.M. Poortmans, L. Collette, J.-C. Horiot, et al, on behalf of the EORTC Radiation Oncology and Breast Cancer Groups) Radiother Oncol 2009; 90: 80-85.
pubmed
• General practitioners and referral for palliative radiotherapy: a population-based survey.
(J.C. Vulto, M. van Bommel, P. Poortmans, M. Lybeert, M. Louwman, R. Baart, J.W. Coebergh) Radiother Oncol 2009; 91: 267-270.
pubmed
• Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer.
(J.C. Vulto, M.L. Lybeert, M.W. Louwman, P.M. Poortmans, J.W. Coebergh) Int J Radiat Oncol Biol Phys 2009; 74: 464-471.
pubmed




2008

• Huisartsen en palliatieve radiotherapie in Nederland.
(J.M.P. Van Bommel, J.C.M. Vulto, P.M.P. Poortmans, M.L.M. Lybeert, W.J. Louwman, J.W.W. Coebergh) Ned Tijdsch Palliat Zorg 2008; 9: 16-21.

• Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century.
(T. Budiharto, E. Musat, P. Poortmans, C. Hurkmans, A Monti, et al) Radiother Oncol 2008; 88: 403-410.
pubmed
• Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'
(S. Collette, L. Collette, T. Budiharto, J.C. Horiot, P.M. Poortmans, et al) Eur J Cancer 2008; 44: 2587-2599.
pubmed
• Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
(H. Goldberg, R.C. Miller, R. Abdah-Bortnyak, M. Steiner, F. Yildiz, et al) Gynecol Oncol 2008; 108: 298-305.
pubmed
• The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.
(T. Girinsky, L. Specht, M. Ghalibafian, V. Edeline, G. Bonniaud, et al) Radiother Oncol 2008; 88: 202-210.
pubmed
• Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.
(W. Jeanneret-Sozzi, A. Taghian, R. Epelbaum, P. Poortmans, D Zwahlen, et al) BMC Cancer 2008; 8: 86.
pubmed
• Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder
(P.M.P. Poortmans, P. Richaud, L. Collette, S. Ho Goey, M. Pierart, M. Van Der Hulst, M. Bolla, on behalf of the EORTC Radiation Oncology Group) Acta Oncol 2008;47:937-940.
pubmed
• The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
(P.M.P. Poortmans, L. Collette, H. Bartelink, H. Struikmans, W.F. Van den Bogaert, et al) Cancer Radiother 2008; 12: 565-570.
pubmed
• Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network.
(M.E. Stein, Z. Bernstein, U. Abacioglu, M. Sengoz, R.C. Miller,et al) Am J Med Sci 2008;336:478-88.
pubmed
• Bestraling van borstkankerpatiënten na sparende en na niet-sparende operatie: stand van zaken en ontwikkelingen.
(H. Struikmans, P. Poortmans) Tijdschrift Kanker 2007; 31: 20-25.





2007

• Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881- 10882.
(N. Antonini, H. Jones, J.-C. Horiot, P. Poortmans, H. Struikmans, et al) Radiother Oncol. 2007; 82: 265-271.
pubmed
• Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10882 Trial.
(H. Bartelink, J.-C. Horiot, P.M. Poortmans, H. Struikmans, W. Van den Bogaert, et al) J Clin Oncol 2007; 25: 3259-3265.
pubmed
• Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
(G. Bousquet, C. Confavreux, N. Magné, C.T. de Lara, P. Poortmans, et al) Radiother Oncol 2007; 85: 355-361.
pubmed
• EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
(C. Fermé, H. Eghbali, J.H. Meerwaldt, C. Rieux, J. Bosq, et al) N Engl J Med. 2007; 357: 1916-1927.
pubmed
• Radiotherapy preserves fingers in the management of subungual squamous cell carcinoma, obviating the need for amputation.
(D.A. Grootenboers, P.M. Poortmans, R.L. Haas) Radiother Oncol 2007; 85: 473-476.
pubmed
• Lymfomen in het centraal zenuwstelsel.
(E.O.E.J. Jansen, J.K. Doorduijn, J.E.C. Bromberg, P.M.P. Poortmans, M.J. van den Bent) Ned Tijdschr Hematol 2007; 4: 183-9.

• The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years.
(M. van der Leest, L. Evers, M.J. van der Sangen, P.M. Poortmans, L.V. van de Poll-Franse, et al) Cancer 2007; 109: 1957-1964.
pubmed
• Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes.
(E. Musat, P. Poortmans, W. Van den Bogaert, H. Struikmans, A. Fourquet, et al) Eur J Cancer 2007; 43: 718-724.
pubmed
• A bright future for radiotherapy in breast cancer.
(P. Poortmans) Radiother Oncol 2007; 82: 243-246.
pubmed
• Evidence based radiation oncology: breast cancer.
(P. Poortmans) Radiother Oncol 2007; 84: 84-101.
pubmed
• Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.
(P. Poortmans, A. Bossi, K. Vandeputte, M. Bosset, R. Miralbell, et al) Radiother Oncol 2007; 84: 121-127.
pubmed
• A population-based study of radiotherapy in a cohort of patients with rectal cancer diagnosed between 1996 and 2000. (J.C. Vulto, W.J. Louwman, M.L. Lybeert, P.M. Poortmans, H.J. Rutten, et al) Eur J Surg Oncol. 2007; 33: 993-937.
pubmed
• A population based study of radiotherapy in a cohort of patients with breast cancer diagnosed between 1996 and 2000.
(J.C. Vulto, W.J. Louwman, P.M. Poortmans, L.M. Lybeert, H.J. Rutten, J.W. Coebergh) Eur J Cancer 2007; 43: 1976-1982.
pubmed

Printen